Taiwan HCC Cohort: Immunotherapy with Intra-Arterial Therapy Outcomes

360 patients with unresectable hepatocellular carcinoma from the Taiwan Liver Cancer Association Research Group database, treated between May 2017 and January 2024. The dataset, provided as supplementary material for a study, compares outcomes for patients receiving immunotherapy alone versus combined with intra-arterial therapy. It was uploaded by figshare admin karger and last updated in May 2026.

Use Cases

• Compare overall survival rates based on treatment group (immunotherapy alone vs. combined with IAT).
• Analyze factors associated with worse outcomes, such as Child-Turcotte-Pugh class or portal vein invasion.
• Evaluate objective response rates and duration of response between the two treatment cohorts.
• Conduct propensity score matching analysis for observational cohort studies in oncology.

Strengths

• Includes 360 patients after 1:3 propensity score matching, providing a balanced comparison.
• Reports specific clinical metrics like a 5-year overall survival rate of 28.7% for the IAT group.
• Contains detailed statistical results, including adjusted hazard ratios and confidence intervals for key outcomes.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the Taiwan-specific cohort.

Provenance

Source

Taiwan Liver Cancer Association (TLCA) Research Group database

Collection Method

Retrospective cohort study of patients initiating first-line immunotherapy.

Time Range

May 2017 to January 2024

Freshness

Last updated 2026-05-05 07:55:15; freshness should be verified.

Geography

Taiwan